Abstract

 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses palovarotene (Sohonos): 1 mg, 1.5 mg, 2.5 mg, 5 mg, and 10 mg oral capsule.
 Indication: To reduce the formation of heterotopic ossification in children and adults aged 8 years and above for females and 10 years and above for males with fibrodysplasia (myositis) ossificans progressiva.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
